Response to Combination Therapy in HCV 3a Infected Pakistani Patients
Author Information
Author(s): Ali Ijaz, Khan Sanaullah, Attaullah Sobia, Khan Shahid Niaz, Khan Jabbar, Siraj Sami, Iqbal Aqib, Swati Zahoor A, Idrees Muhammad
Primary Institution: Institute of Biotechnology and Genetic Engineering, KP University of Agriculture, Peshawar, Pakistan
Hypothesis
Mutations within the NS5A gene of HCV 3a genotype may influence the outcome of combination therapy in Pakistani populations.
Conclusion
Mutations within the NS5A gene of HCV 3a genotype may not influence the outcome of combination therapy in Pakistani populations.
Supporting Evidence
- 20 out of 27 patients achieved sustained virological response (SVR).
- 4 patients were non-responders (NR) and 3 exhibited end of treatment response (ETR).
- Mutations were found in the NS5A gene, but did not correlate with treatment outcomes.
Takeaway
This study looked at patients with a virus called HCV and found that changes in a specific part of the virus didn't really affect how well the treatment worked.
Methodology
Patients were treated with IFN-α and ribavirin for six months, and the NS5A gene was sequenced to analyze mutations.
Limitations
The study did not find significant correlations between NS5A mutations and treatment response.
Participant Demographics
30 patients (13 women, 17 men, average age 40 years, range 20-60 years) chronically infected with HCV subtype 3a.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website